Organizing Pneumonia: A Clinical Challenge in a Child With Previous Rhabdomyosarcoma

Ricardo Barreto Mota1, Diogo Costa Carvalho1, Inês Azevedo1,2

  • 1Centro Hospitalar Universitário de São João, Porto, Portugal.

Insights

Organizing pneumonia is a rare lung disease. This case highlights its potential occurrence in adolescents with a history of rhabdomyosarcoma, emphasizing diagnostic considerations.

Area of Science:

  • Pulmonology
  • Pediatric Oncology
  • Radiology

Background:

  • Organizing pneumonia is a rare pulmonary disease with an unknown cause, infrequently reported in children.
  • It can arise secondary to treatments like chemotherapy, radiation therapy, or hematopoietic cell transplantation.

Observation:

  • An 18-year-old male presented with respiratory symptoms 8 years post-treatment for rhabdomyosarcoma.
  • Imaging revealed nodular opacities and ground-glass opacities in the lungs, with one cavitated lesion.

Findings:

  • Microbiological work-up, including tuberculosis screening, was negative.
  • A biopsy confirmed findings suggestive of organizing pneumonia.
  • The patient experienced spontaneous resolution of symptoms.

Implications:

  • This case underscores the importance of considering organizing pneumonia in patients with pulmonary lesions and a history of specific treatments (e.g., stem cell transplant, lung irradiation, immunosuppression).
  • Pulmonary metastases and secondary tumors should be differential diagnoses in patients with relapsed rhabdomyosarcoma.
  • The diagnostic challenge presented by this rare condition in a pediatric oncology patient is highlighted.

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
365
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
486
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.5K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
811
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
470